WHO WE ARE?
We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our teams of experts based on our 3 sites, in Europe and in the US, are devoted to support innovative projects and help to reduce overall timelines and costs.
Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations.
We offer a broad range of viral vectors, including AAV, LVV, MVA, Poxvirus, Vaccinia, Measles, and more.
Our CDMO services include manufacturing of bulk drug substance, fill-finish of drug products, process and assay development, bioanalytical testing and regulatory support.
We place the client at the heart of everything we do. We implement strategies to achieve Best-class Customer Experience. A team of experts is dedicated to your project to provide you the best innovative solutions adapted to your needs in order to meet your expectations.
first viral vector facility in Europe
(France & USA)
years of experience
in viral vectors
- Fill & up to
ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of oncolytic viruses, gene therapies, and vaccine candidates based on viral vectors.
We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897.
As a pioneer, we have been developing and producing virus vector since 1990s. We started with Pox Virus, MVA, Vaccinia and oncolytic viruses to support our clients’ clinical trials with the final goal of fighting against smallpox and several types of cancer.
We have continuously added new viruses within our portfolio, including manufacturing of AAVs in 2016 through adherent and suspension processes. Based on this strong expertise in virology and cell culture, in 2022 we decided to develop our high predictable yield and versatile AAV platform to manufacture different serotypes.
More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world.
Bionetic Research Laboratory est créé
Acquisition par Litton Industries. Activités élargies aux rétrovirus et à la recherche contre le cancer
Organon Teknika acquiert des actifs de R&D et de diagnostic, et renomme la société ABL
bioMérieux acquiert ABL, qui devient une société du groupe Institut Mérieux
ABL devient une société dérivée de bioMérieux, une société sœur, sous l’égide de l’Institut Mérieux
ABL établi son siège social à Rockville, MD (Etats Unis)
ABL acquiert Platine Pharma à Lyon and construit les laboratoires de test GCLP
Création de la première entité en France, à travers l’acquisition des actifs de production de Transgene à Strasbourg*
* Expansion des capacités d’ABL grâce à l’usine de fabrication de vecteurs viraux, certifiée GMP en 1995.
Création de la seconde entité d’ABL entity en France, à travers l’acquisition de la plateforme innovante Accinov à Lyon
Today, ABL is fully owned by Institut Mérieux.
OUR MISSION & VISION
OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world.
OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We empower people. We foster an entrepreneurial culture. We commit to sustainability.
WHAT DO WE OFFER?
Your solution provider
Developing and manufacturing viral vectors for over 25 years
Dedicated project management
Effective quality control capabilities essential for your success
Flexibility within our contracts
Talented teams to deliver the highest level of services